<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161625">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142595</url>
  </required_header>
  <id_info>
    <org_study_id>20140515</org_study_id>
    <nct_id>NCT02142595</nct_id>
  </id_info>
  <brief_title>Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing TURP</brief_title>
  <official_title>Comparison of the Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing Transurethral Prostatic Resection(TURP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed a study to determine whether dexmedetomidine versus midazolam
      combined with spinal anesthesia would provide same postoperative sleep quality in patients
      undergoing transurethral prostatic resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a study to determine whether dexmedetomidine versus midazolam
      combined with spinal anesthesia would provide same postoperative sleep quality in patients
      undergoing transurethral prostatic resection.The bispectral index score (BIS) was monitored
      during the operation.The sleep quality will be test with Pittsburgh sleep quality index
      (PSQI)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Change of postoperative sleep quality</measure>
    <time_frame>preoperation, first and second postoperative night</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All patients underwent baseline Pittsburgh sleep quality index (PSQI) were assessed one day before operation, postoperative first and second night. The primary outcome measure is change of PSQI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of interleukin-6 level in cerebrospinal fluid (CSF) and plasma samples</measure>
    <time_frame>preoperation and the third postoperative day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>CSF samples were obtained using lumbar puncture in the L2-L3 or L3-L4 intervertebral space. After a successful puncture, 3 mL of CSF was obtained and collected in polypropylene tubes and brought to the laboratory immediately. The blood samples were collected before induction of anesthesia and 3 days after the end of surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postoperative delirium</measure>
    <time_frame>3 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Postoperative delirium was tested with CAM-ICU 3 days after surgery</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sleep Quality of Patients Undergoing TURP</condition>
  <arm_group>
    <arm_group_label>dexmeditomidine group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 μg/kg dexmedetomidine infusion for sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam group M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-3mg midazolam for sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients accept spinal anesthesia with saline sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>dexmedetomidine 1 μg/kg</description>
    <arm_group_label>dexmeditomidine group D</arm_group_label>
    <other_name>dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam 2-3 mg</description>
    <arm_group_label>Midazolam group M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants were deemed eligible if they were candidates for spinal anesthesia
             undergoing TURP

        Exclusion Criteria:

          -  Existing cognitive impairment as evidenced by Mini-Mental State Examination scores
             below 24 (of the 30 possible points)

          -  A history of neurological and psychiatric diseases including stroke, and psychosis

          -  Severe visual or hearing impairment

          -  Unwillingness to comply with the protocol or procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Ma, M.D.,PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology the first hospital of CMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenfei Tan, M.D.,PhD.</last_name>
    <phone>024-83283100</phone>
    <email>winfieldtan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Ma, M.D.,PhD</last_name>
      <phone>86-024-83283100</phone>
      <email>mahong5466@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Wenfei Tan, M.D.,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Wen-fei Tan</investigator_full_name>
    <investigator_title>the Anesthesiology Department</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>midazolam</keyword>
  <keyword>sleep quality</keyword>
  <keyword>delirium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
